

RECEIVED CENTRAL FAX CENTED

DEC 22 zwa

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/509,633	Applicant: Jean-Claude Amould
371 Filing Date: 09/29/2004	Attorney Docket No.: 100467-1P US
Examiner: Grazier, Nyeemah	Group Art Unit : 1626
Customer No.: 44992	Confirmation No.: 4294
Title: INDOLE DERIVATIVES HAVING	G ANTI-ANGIOGENETIC ACTIVITY

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on 22 December 2005

Signature Lucy Padget

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the Non-Final Office Action dated 12/13/2005, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks/Arguments begin on page 8 of this paper.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmac∋uticals LP
35 Gatehouse Drive
Waltham MA 02451

Tel +1 781-839-4000

Fax +1 781-839-4500